| Changes of BMD
and Bone Turnover Marker after Estrogen and Alendronate Therapy in Postmenopausal Women with Osteoporosis |
| 폐경후 여성에서 여성호르몬과 알렌드로네이트 치료약제에 따른 골밀도와 골대사 표지물질의 변화 |
|
박동희; 김의현; 김원호; 김성재; 김희경; 이상원; 이인규 |
|
|
|
|
| Abstract |
|
The aim of this study was to
investigate the effect of different classes of drugs; which are currently available for the treatment of osteoporosis. Forty nine postmenopausal women with osteoporosis participated in this study. Subjects were divided into IV groups: Group I was treated with activated vitamin D; Group II with estrogen; Group III with alendronate; and Group IV with estrogen and alendronate. Treatment duration was one year. The levels of serum calcium; phosphorous and alkaline phosphate (ALP) and urine deoxypyridinoline(DPD); osteocalcin and bone mineral densities (BMD) were determined before and after the treatment. The total serum ALP and osteocalcin were significantly decreased; and BMD was significantly increased in Group IV. However; significant difference in the markers to indicate bone metabolism was not found among Group I; II and III. The present study showed the combination therapy of alendronate and estrogen to be the most effective in improving BMD and tone chemical marker. |
| Key Words:
Alendronate,
Biochemical marker, Hormone replacement therapy, Osteoporosis |
PDF Links
Full text via DOI
Download Citation
